Xilio Therapeutics Unveils Promising Phase 2 Data for Vilastobart in MSS Colorectal Cancer at SITC 2025
Dateline – Waltham, Massachusetts, October 30, 2025:Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company pioneering tumor-activated immuno-oncology therapies,...
